menu
    • menu
    [{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Atezolizumab","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Merck Group","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Avelumab","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck Group \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Exelixis"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bristol Myers Squibb \/ Exelixis","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Exelixis"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"PTK","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"GRP78 upregulation pathway","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"Tyrosine kinase","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"TYK","graph1":"Oncology","graph2":"Phase I","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Exelixis \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Exelixis \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Bold Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Bold Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bold Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Bold Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"XyloCor Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"XyloCor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"XyloCor Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"XyloCor Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Exelixis","sponsor":"Arcus Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Arcus Biosciences","highestDevelopmentStatusID":"5","companyTruncated":"Exelixis \/ Arcus Biosciences"},{"orgOrder":0,"company":"Exelixis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Exelixis \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Exelixis \/ Not Applicable"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Casdatifan","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Arcus Biosciences \/ Hercules Capital"},{"orgOrder":0,"company":"Exelixis","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Encoberminogene Rezmadenovec","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Exelixis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Exelixis \/ Merck & Co","highestDevelopmentStatusID":"12","companyTruncated":"Exelixis \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals for Encoberminogene Rezmadenovec

    Menu

    Encoberminogene Rezmadenovec

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Exelixis & Merck Collaborate on Zanzalintinib + KEYTRUDA® for Head/Neck Cancer & RCC

                            Details : The collaboration aims to evaluate Exelixis’ TKI XL092 (zanzalintinib) with Merck’s Keytruda (pembrolizumab) for HNSCC, and with Welireg (belzutifan), an oral HIF-2 alpha inhibitor, for RCC.

                            Brand Name : XL092

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 14, 2024

                            Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Arcus Biosciences

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Casdatifan,Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hercules Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

                            Details : The proceeds will be used to rapidly advance AB521 (casdatifan), its potential best-in-class HIF-2a inhibitor, for the treatment of renal cell cancer.

                            Brand Name : AB521

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 27, 2024

                            Lead Product(s) : Casdatifan,Encoberminogene Rezmadenovec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hercules Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,AB521

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Arcus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination ...

                            Details : The companies will enter into a clinical trial collaboration evaluating XL092 (zanzalintinib), a tyrosine kinase inhibitor, in combination with AB521 in patients with advanced solid tumors including clear cell renal cell carcinoma.

                            Brand Name : XL092

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 04, 2023

                            Lead Product(s) : Encoberminogene Rezmadenovec,AB521

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Arcus Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combinati...

                            Details : XL092 (Zanzalintinib) is a Vegf/metaxl/mer Inhibitor small molecule drug candidate, which is currently being evaluated in combination with "Pembrolizumab" for the treatment of PD-L1-positive recurrent or metastatic squamous cell carcinoma of the head and...

                            Brand Name : XL092

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 04, 2023

                            Lead Product(s) : Encoberminogene Rezmadenovec,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            XyloCor Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            XyloCor Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            XyloCor Therapeutics Reports Sustained Results in 12-Month Extension of Phase 2 EXACT Clinical Trial of XC001 ...

                            Details : XC001 (encoberminogene rezmadenovec) is designed to promote new blood vessels in the heart that will bypass diseased blood vessels and improve blood flow in patients with refractory angina.

                            Brand Name : XC001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 18, 2023

                            Lead Product(s) : Encoberminogene Rezmadenovec

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients wi...

                            Details : Zanzalintinib, which was adopted as the generic name for XL092, is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types. Zanzalintinib is currently being developed for the treatment of advanced solid tumors.

                            Brand Name : XL092

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 22, 2022

                            Lead Product(s) : Encoberminogene Rezmadenovec,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Bold Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bold Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bold Therapeutics Attending and Presenting at the BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences

                            Details : BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that alters the unfolded protein response (UPR) through selective GRP78 inhibition and induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest.

                            Brand Name : BOLD-100

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 14, 2022

                            Lead Product(s) : Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fi...

                            Details : XL092 is a next-generation oral TKI that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER.

                            Brand Name : XL092

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : Encoberminogene Rezmadenovec,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Exelixis

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Co...

                            Details : XL092 demonstrated preliminary clinical activity similar to that observed with cabozantinib in phase 1 across a range of solid tumors and dose levels, with a manageable safety profile.

                            Brand Name : XL092

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 10, 2022

                            Lead Product(s) : Encoberminogene Rezmadenovec,Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Bold Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Bold Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bold Therapeutics BOLD-100 Early mCRC Data to be Showcased at 2022 Metals in Medicine Gordon Research Conferen...

                            Details : BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition.

                            Brand Name : BOLD-100

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 24, 2022

                            Lead Product(s) : Encoberminogene Rezmadenovec,Oxaliplatin,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth